Lindsey B. Gottlieb

Lindsey B. Gottlieb

Auto-generated profile, based on publicly available information

Lindsey B. Gottlieb

Emory University School of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 October 2021 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
LGLindsey B. Gottlieb
Lindsey B. Gottlieb
EWEmily Walits
Emily Walits
GPGopi Patel
Gopi Patel
SSSarah Schaefer
Sarah Schaefer
Contact precautions are used to prevent the spread of extended-spectrum β-lactamase (ESBL)–producing organisms in acute-care hospitals, but supporting data are lacking. We discontinued such precautions for ESBL Escherichia coli and Klebsiella spp and found no increased prevalence of these organisms with our change in practice.

14 February 2024 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
JHJessica R. Howard-Anderson
Jessica R. Howard-Anderson
LGLindsey B. Gottlieb
Lindsey B. Gottlieb
SBSusan E. Beekmann
Susan E. Beekmann
PPPhilip M. Polgreen
Philip M. Polgreen
JJJesse T. Jacob
Jesse T. Jacob
DUDaniel Z. Uslan
Daniel Z. Uslan
Objective: To understand how healthcare facilities employ contact precautions for patients with multidrug-resistant organisms (MDROs) in the post–coronavirus disease 2019 (COVID-19) era and explore changes since 2014.Design: Cross-sectional survey.Participants: Emerging Infections Network (EIN) physicians involved in infection prevention or hospital epidemiology.Methods: In September 2022, we sent via email an 8-question survey on contact precautions and adjunctive measures to reduce MDRO transmission in inpatient facilities. We also asked about changes since the COVID-19 pandemic. We used descriptive statistics to summarize data and compared results to a similar survey administered in 2014.Results: Of 708 EIN members, 283 (40%) responded to the survey and 201 reported working in infection prevention. A majority of facilities (66% and 69%) routinely use contact precautions for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE) respectively, compared to 93% and 92% in 2014. Nearly all (>90%) use contact precautions for Candida auris, carbapenem-resistant Enterobacterales (CRE), and carbapenem-resistant Acinetobacter baumannii. More variability was reported for carbapenem-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase–producing gram-negative organisms. Compared to 2014, fewer hospitals perform active surveillance for MRSA and VRE. Overall, 90% of facilities used chlorhexidine gluconate bathing in all or select inpatients, and 53% used ultraviolet light or hydrogen peroxide vapor disinfection at discharge. Many respondents (44%) reported changes to contact precautions since COVID-19 that remain in place.Conclusions: Heterogeneity exists in the use of transmission-based precautions and adjunctive infection prevention measures aimed at reducing MDRO transmission. This variation reflects a need for updated and specific guidance, as well as further research on the use of contact precautions in healthcare facilities.

1 June 2021 in American Journal of Infection Control
Verified
Journal Article
Open access
BSBarbara A. Smith
Barbara A. Smith
KKKilyoub Kim
Kilyoub Kim
AYArsheena Yassin
Arsheena Yassin
BCBernard Camins
Bernard Camins
LGLindsey Gottlieb
Lindsey Gottlieb
During the first three months of the COVID 19 pandemic, our facility cared for an influx of patients. At the peak, the daily census exceeded 200 patients with COVID 19. Surveillance for healthcare acquired infections (HAIs) continued throughout this time. Despite the acuity of the patients and the frequent use of antibiotics, the rates of Clostridioides difficile lab ID (CDI) events remained relatively stable. We sought to determine the validity of this rate. To determine if cases of CDI were missed, we compared the 3-month rate per 10,000 patient days in 2020 to the same time-period in 2019 (March, April, and May). The number of tests ordered during the two periods was also compared. Additionally, the Doctor of Pharmacy from our antibiotic stewardship team reviewed all orders for oral Vancomycin to determine if empiric CDI treatment was initiated without confirmatory testing. The CDI rate for the 3 months in 2019 was zero compared to 0.48 per 10,000 patient days during the peak of the pandemic. The number of tests increased in the 2020 period to 17.5 per 10,000 patient days versus 15.8 in the 2019 period. Three patients received oral Vancomycin, each of whom had valid indications. Based on this data, CDI cases were not underreported. We speculate that the lack of an increase in CDI rates may be attributed to: Increased hand hygiene by staff – compliance increased to 91 % in 2020 compared to 83 % in 2019,enhanced attention to cleaning and high level disinfection, and Improved adherence to use of personal protective equipment.

25 June 2026 in American Journal of Infection Control
Verified
Journal Article
Open access
JHJessica R. Howard-Anderson
Jessica R. Howard-Anderson
VDVictoria R. Dotto
Victoria R. Dotto
LGLindsey B. Gottlieb
Lindsey B. Gottlieb
LGLori Grooms
Lori Grooms
CHCarolyn Holder
Carolyn Holder
JMJoel M. Mumma
Joel M. Mumma
During the COVID-19 pandemic, central line-associated bloodstream infections (CLABSIs) and catheter-associated urinary tract infections (CAUTIs) increased substantially across US hospitals. We performed qualitative analyses of free-text contributing factors reported in apparent cause analyses (ACAs) of CLABSIs and CAUTIs occurring August 2020-August 2022 within an academic healthcare system in Atlanta, GA. We developed a framework for classifying contributing factors in terms of critical infection prevention tasks as well as issues affecting these tasks. We reviewed 350 CLABSI ACAs with 602 contributing factors and 240 CAUTI ACAs with 405 contributing factors. The framework comprised 9 CLABSI-specific and 7 CAUTI-specific tasks and 11 issues affecting tasks for both infection types. The tasks most frequently implicated in CLABSIs were patient bathing (29%) and central line dressing maintenance (23%); in CAUTIs, the most frequent tasks were urinary catheter care (37%) and the assessment of catheter necessity (32%). Although these tasks were affected by nearly every issue, documentation gaps and knowledge or skills deficits were particularly prevalent, with the latter being the primary issue for some infrequently reported tasks (eg, drawing blood from central lines and use of bowel management systems). This task-issue framework links infection prevention tasks to systemic issues that undermine their performance and may help quality improvement teams monitor trends and design targeted interventions to strengthen CLABSI and CAUTI prevention.

14 October 2024 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
LGLindsey B. Gottlieb
Lindsey B. Gottlieb
RPRadhika Prakash-Asrani
Radhika Prakash-Asrani
WDWilliam Dube
William Dube
ZWZanthia Wiley
Zanthia Wiley
GLGiancarlo Licitra
Giancarlo Licitra
SFScott K. Fridkin
Scott K. Fridkin
Objective: To examine the relationship between race and ethnicity and central line-associated bloodstream infections (CLABSI) while accounting for inherent differences in CLABSI risk related to central venous catheter (CVC) type.Design: Retrospective cohort analysis.Setting: Acute care facilities within an academic healthcare system.Patients: Adult inpatients from January 2012 through December 2017 with CVC present for ≥2 contiguous days.Methods: We describe variability in demographics, comorbidities, CVC type/configuration, and CLABSI rate by patient’s race and ethnicity. We estimated the unadjusted risk of CLABSI for each demographic and clinical characteristic and then modelled the effect of race on time to CLABSI, adjusting for total parenteral nutrition use and CVC type. We also performed exploratory analysis replacing race and ethnicity with social vulnerability index (SVI) metrics.Results: 32,925 patients with 57,642 CVC episodes met inclusion criteria, most of which (51,348, 89%) were among non-Hispanic White or non-Hispanic Black patients. CVC types differed between race/ethnicity groups. However, after adjusting for CVC type, configuration, and indication in an adjusted cox regression, the risk of CLABSI among non-Hispanic Black patients did not significantly differ from non-Hispanic White patients (adjusted hazard ratio [aHR] 1.19; 95% confidence interval [CI]: 0.94, 1.51). The odds of having a CLABSI among the most vulnerable SVI subset compared to the less vulnerable was no different (odds ratio [OR] 0.95; 95% CI: 0.75–1.2).Conclusions: We did not find a difference in CLABSI risk between non-Hispanic White and non-Hispanic Black patients when adjusting for CLABSI risk inherent in type and configuration of CVC.

1 June 2023 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
JHJessica Howard-Anderson
Jessica Howard-Anderson
LGLindsey Gottlieb
Lindsey Gottlieb
SBSusan E. Beekmann
Susan E. Beekmann
PPPhilip M Polgreen
Philip M Polgreen
JJJesse T. Jacob
Jesse T. Jacob
DUDaniel Z. Uslan
Daniel Z. Uslan
Background: The CDC recommends routine use of contact precautions for patients infected or colonized with multidrug-resistant organisms (MDROs). There is variability in implementation of and adherence to this recommendation, which we hypothesized may have been exacerbated by the COVID-19 pandemic. Methods: In September 2022, we emailed an 8-question survey to Emerging Infections Network (EIN) physician members with infection prevention and hospital epidemiology responsibilities. The survey asked about the respondent’s primary hospital’s recommendations on transmission-based precautions, adjunctive measures to reduce MDRO transmission, and changes that occurred during the COVID-19 pandemic. We sent 2 reminder emails over a 1-month period. We used descriptive statistics to summarize the data and to compare results to a similar EIN survey (n = 336) administered in 2014 (Russell D, et al. doi:10.1017/ice.2015.246). Results: Of 708 EIN members, 283 (40%) responded to the survey, and 201 were involved in infection prevention. Most respondents were adult infectious diseases physicians (n = 228, 80%) with at least 15 years of experience (n = 174, 63%). Respondents were well distributed among community, academic, and nonuniversity teaching facilities (Table 1). Most respondents reported that their facility routinely used CP for methicillin-resistant Staphylococcus aureus (MRSA, 66%) and vancomycin-resistant Enterococcus (VRE, 69%), compared to 93% and 92% respectively, in the 2014 survey. Nearly all (>90%) reported using contact precautions for Candida auris, carbapenem-resistant Enterobacterales (CRE), and carbapenem-resistant Acinetobacter spp, but there was variability in the use of contact precautions for carbapenem-resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase–producing gram-negative organisms. In 2014, 81% reported that their hospital performed active surveillance testing for MRSA, and in 2022 this rate fell to 54% (Table 2). The duration of contact precautions varied by MDRO (Table 3). Compared to 2014, in 2022 facilities were less likely to use contact precautions indefinitely for MRSA (18% vs 6%) and VRE (31% vs 11%). Also, 180 facilities (90%) performed chlorhexidine bathing in at least some inpatients and 106 facilities (53%) used ultraviolet light or hydrogen peroxide vapor disinfection at discharge in some rooms. Furthermore, 89 facilities (44%) reported institutional changes to contact precautions policies after the start of the COVID-19 pandemic that remain in place. Conclusions: Use of contact precautions for patients with MDROs is heterogenous, and policies vary based on the organism. Although most hospitals still routinely use contact precautions for MRSA and VRE, this practice has declined substantially since 2014. Changes in contact-precaution policies may have been influenced by the COVID-19 pandemic, and more specifically, contemporary public health guidance is needed to define who requires contact precautions and for what duration. Disclosures: None